Drug Search Results
More Filters [+]

Vincristine

Alternative Names: vincristine, vincristina, marqibo, oncovin, Vincristine Sulfate, vincristin, vincasar pfs, vincrex
Latest Update: 2024-02-16
Latest Update Note: Clinical Trial Update

Product Description

Vincristine is a chemotherapy drug that belongs to a group of drugs called vinca alkaloids. Vincristine works by stopping the cancer cells from separating into 2 new cells. (Sourced from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/vincristine)

Mechanisms of Action: Mitosis Inhibitor,Tubulin Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Acute Leukemia | Acute Lymphoid Leukemia | Leukemia | Lymphoid Leukemia

Known Adverse Events: Insomnia | Anemia | Febrile Neutropenia | Neutropenia | Constipation | Diarrhea

Company: Premier Inc
Company Location:
Company CEO:
Additonal Commercial Interests: Pfizer

Clinical Description

Map of Global Clinical Trials for Vincristine

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, Korea, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Philippines, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Slovakia, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Acute Lymphoid Leukemia|Brain Cancer|Breast Cancer|Diffuse Large B-Cell Lymphoma|Glioma|Hodgkin Lymphoma|Leukemia|Lymphoid Leukemia|Lymphoma|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Neuroblastoma|Non-Small-Cell Lung Cancer|Other|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Sarcoma, Ewing|T-Cell Peripheral Lymphoma

Phase 2: B-Cell Leukemia|COVID-19|Fetal Diseases|Follicular Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Pregnancy Complications, Infectious|Pregnancy Outcomes|Retinoblastoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

HR-NBL2

P3

Active, not recruiting

Neuroblastoma

2031-09-24

iEuroEwing

P3

Recruiting

Sarcoma, Ewing

2031-05-31

2019-004153-93

P3

Active, not recruiting

Sarcoma, Ewing

2030-12-17

2018-005027-16

P3

Active, not recruiting

Glioma

2030-09-14

Recent News Events